Poseida Therapeutics Expands Into JLABS

Poseida Therapeutics, a privately held human therapeutics spinout of Transposagen Biopharmaceuticals, has begun drug development operations at its new location at JLABS in San Diego, CA.

The drug development and license agreement between Transposagen and Janssen, which was announced in November of 2014, has been transferred to Poseida. The three-year drug development partnership and license agreement will focus on developing at least two allogeneic CAR-T product candidates. Poseida will receive milestone payments of up to $292 million per product candidate and tiered royalty payments. Both companies will work together on preclinical development and Janssen will be responsible for manufacturing and commercialization.

The 40,000 square foot San Diego JLABS facility features core research labs hosting specialized capital equipment, shared administrative areas and individual bench, wet lab and office modules.